Advertisement
Heart, Lung and Circulation

Post-Discharge Antithrombotic Therapy Following Transcatheter Aortic Valve Implantation in Australian Patients

      Background

      Guidelines recommend antithrombotic therapy for patients following transcatheter aortic valve implantation (TAVI) to reduce the risk of ischaemic events and bioprosthetic valve thrombosis.

      Objective

      To describe antithrombotic dispensing within 30 days of discharge for Australian patients receiving TAVI.

      Methods

      We performed a state-wide retrospective cohort study using linked hospital and medicines dispensing data from January 2013 to December 2018 for all patients receiving TAVI in New South Wales, Australia. We identified patients dispensed oral anticoagulants (vitamin K antagonists [warfarin], direct oral anticoagulants [DOACs]) or clopidogrel within 30 days of discharge. We examined demographic and clinical predictors of antithrombotic dispensing.

      Results

      Our cohort comprised 1,217 patients who underwent TAVI; median age was 84 years and 707 (58.1%) were male. Of these, 808 patients (66.4%) had an antithrombotic dispensed within 30 days of hospital discharge. One-third (33.7%) of these patients were dispensed an anticoagulant (16.1% warfarin; 17.6% DOACs) and two-thirds (66.3%) were dispensed clopidogrel. Patients undergoing TAVI were more likely to be dispensed an antithrombotic medicine within 30-days of hospital discharge if they had been dispensed antithrombotic medicines (RR 1.07; 95% CI 1.03–1.11) or angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers (RR 1.04; 95% CI 1.00–1.07) in the 6 months prior to admission. Patients with a history of haemorrhage were less likely to be dispensed an antithrombotic medicine within 30 days of hospital discharge (RR 0.93; 95% CI 0.89–0.98).

      Conclusions

      We observed gaps in best evidence pharmacotherapy for patients post-TAVI, with almost one third of patients not receiving antithrombotic medicines post-discharge. Further research is needed to quantify the impact of emerging clinical guidelines recommending single antiplatelet therapy, on adherence to best-practice care.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nelson A.J.
        • Montarello N.J.
        • Cosgrove C.S.
        • Roberts-Thomson R.L.
        • Delacroix S.
        • Chokka R.G.
        • et al.
        Transcatheter aortic valve implantation: a new standard of care.
        Med J Aust. 2018; 209: 136-141
        • Vahanian A.
        • Beyersdorf F.
        • Praz F.
        • Milojevic M.
        • Baldus S.
        • Bauersachs J.
        • et al.
        2021 ESC/EACTS Guidelines for the management of valvular heart disease.
        Eur J Cardiothoracic Surg. 2021; 43: 561-632
        • Otto C.M.
        • Nishimura R.A.
        • Bonow R.O.
        • Carabello B.A.
        • Erwin J.P.
        • Gentile F.
        • et al.
        2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
        Circulation. 2021; 143: e72-e227
        • Baumgartner H.
        • Falk V.
        • Bax J.J.
        • De Bonis M.
        • Hamm C.
        • Holm P.J.
        • et al.
        2017 ESC/EACTS Guidelines for the management of valvular heart disease.
        Eur Heart J. 2017; 38: 2739-2791
        • Huiart L.
        • Ferdynus C.
        • Renoux C.
        • Beaugrand A.
        • Lafarge S.
        • Bruneau L.
        • et al.
        Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases.
        BMJ Open. 2018; 8e018180
        • Cerrato E.
        • Nombela-Franco L.
        • Nazif T.M.
        • Eltchaninoff H.
        • Søndergaard L.
        • Ribeiro H.B.
        • et al.
        Evaluation of current practices in transcatheter aortic valve implantation: the WRITTEN (WoRldwIde TAVI ExperieNce) survey.
        Int J Cardiol. 2017; 228: 640-647
        • Nijenhuis V.J.
        • Stella P.R.
        • Baan J.
        • Brueren B.R.G.
        • de Jaegere P.P.
        • den Heijer P.
        • et al.
        Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals.
        Neth Heart J. 2014; 22: 64-69
        • Sherwood M.W.
        • Vemulapalli S.
        • Harrison J.K.
        • Dai D.
        • Vora A.N.
        • Mack M.J.
        • et al.
        Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry.
        Am Heart J. 2018; 204: 9-16
        • Ahmad Y.
        • Demir O.
        • Rajkumar C.
        • Howard J.P.
        • Shun-Shin M.
        • Cook C.
        • et al.
        Optimal antiplatelet strategy after transcatheter aortic valve implantation: a meta-analysis.
        Open Heart. 2018; 5e000748
        • Falster M.O.
        • Schaffer A.L.
        • Wilson A.
        • Nasis A.
        • Jorm L.R.
        • Hay M.
        • et al.
        Evidence-practice gaps in P2Y12 inhibitor use after hospitalisation for acute myocardial infarction: findings from a new population-level data linkage in Australia.
        Intern Med J. 2020; 52: 249-258
        • Schaffer A.L.
        • Falster M.O.
        • Brieger D.
        • Jorm L.R.
        • Wilson A.
        • Hay M.
        • et al.
        Evidence-practice gaps in postdischarge initiation with oral anticoagulants in patients with atrial fibrillation.
        J Am Heart Assoc. 2019; 8e014287
        • Hsu B.
        • Falster M.O.
        • Schaffer A.L.
        • Pearson S.
        • Jorm L.R.
        • Brieger D.B.
        • et al.
        Antiplatelet therapy within 30 days of percutaneous coronary intervention with stent implantation.
        Med J Aust. 2020; 213: 124-125
      1. Victorian Agency for Health Information. Delivering better cardiac outcomes in Victoria. Melbourne: 2019. https://www.bettersafercare.vic.gov.au/sites/default/files/2019-06/VAHI%20Delivering%20better%20cardiac%20outcomes%20report_8%20JUNE%202019.pdf. [accessed 31.8.21].

      2. Australian Institute of Health and Welfare. Admitted patient care 2016–17: Australian hospital statistics. Health services series no. 84. Cat. no. HSE 201. Canberra: 2018. https://www.aihw.gov.au/getmedia/acee86da-d98e-4286-85a4-52840836706f/aihw-hse-201.pdf.aspx?inline=true. [accessed 31.8.21].

        • Mellish L.
        • Karanges E.A.
        • Litchfield M.J.
        • Schaffer A.L.
        • Blanch B.
        • Daniels B.J.
        • et al.
        The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers.
        BMC Res Notes. 2015; 8: 634
        • Australian Consortium for Classification Development
        The international statistical classification of diseases and related health problems, tenth revision, australian modification (ICD-10-AM/ACHI/ACS).
        Australian Consortium for Classification Development, Darlinghurst, NSW2017
      3. Department of Health. 2. Prescribing Medicines – Information for PBS Prescribers. Canberra: 2015. https://www.pbs.gov.au/info/healthpro/explanatory-notes/section1/Section_1_2_Explanatory_Notes#Restrictions. [accessed 31.8.21].

        • Agewall S.
        • Cattaneo M.
        • Collet J.P.
        • Andreotti F.
        • Lip G.Y.H.
        • Verheugt F.W.A.
        • et al.
        Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
        Eur Heart J. 2013; 34: 1708-1713
      4. Australian Bureau of Statistics. 2039.0 - Information Paper: An Introduction to Socio-Economic Indexes for Areas (SEIFA), 2006. Canberra: 2008. https://www.abs.gov.au/ausstats/[email protected]/mf/2039.0. [accessed 31.8.21].

      5. Australian Institute of Health and Welfare. Regional and remote health: A guide to remoteness classifications. Canberra: 2004. https://www.aihw.gov.au/reports/rural-remote-australians/guide-to-remoteness-classifications/summary. [accessed 31.7.21].

        • Sundararajan V.
        • Henderson T.
        • Perry C.
        • Muggivan A.
        • Quan H.
        • Ghali W.A.
        • et al.
        New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality.
        J Clin Epidemiol. 2004; 57: 1288-1294
        • Gilbert T.
        • Neuburger J.
        • Kraindler J.
        • Keeble E.
        • Smith P.
        • Ariti C.
        • et al.
        Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study.
        Lancet. 2018; 391: 1775-1782
        • Zou G.
        A modified Poisson regression approach to prospective studies with binary data.
        Am J Epidemiol. 2004; 159: 702-706
        • Ray W.A.
        Evaluating medication effects outside of clinical trials: new-user designs.
        Am J Epidemiol. 2003; 158: 915-920
        • Funk M.J.
        • Landi S.N.
        Misclassification in administrative claims data: quantifying the impact on treatment effect estimates.
        Curr Epidemiol Reports. 2014; 1: 175
        • Guedeney P.
        • Mehran R.
        • Collet J.-P.
        • Claessen B.E.
        • ten Berg J.
        • Dangas G.D.
        • et al.
        Antithrombotic therapy after transcatheter aortic valve replacement.
        Circ Cardiovasc Interv. 2019; 12e007411
        • Rashid H.N.
        • Michail M.
        • Ramnarain J.
        • Nasis A.
        • Nicholls S.J.
        • Cameron J.D.
        • et al.
        The impact of hypo-attenuated leaflet thickening on haemodynamic valve deterioration following transcatheter aortic valve replacement.
        J Cardiovasc Comput Tomogr. 2021; 16: 168-173
        • Bogyi M.
        • Schernthaner R.E.
        • Loewe C.
        • Gager G.M.
        • Kronberger C.
        • Postula M.
        • et al.
        Subclinical leaflet thrombosis after transcatheter aortic valve replacement: a meta-analysis.
        JACC Cardiovasc Interv. 2021; 14: 2643-2656
        • Jackevicius C.A.
        • Li P.
        • Tu J.V.
        Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction.
        Circulation. 2008; 117: 1028-1036
        • Brouwer J.
        • Nijenhuis V.J.
        • Delewi R.
        • Hermanides R.S.
        • Holvoet W.
        • Dubois C.L.F.
        • et al.
        Aspirin with or without clopidogrel after transcatheter aortic-valve implantation.
        N Engl J Med. 2020; 383: 1447-1457
        • Rodés-Cabau J.
        • Masson J.-B.
        • Welsh R.C.
        • Garcia del Blanco B.
        • Pelletier M.
        • Webb J.G.
        • et al.
        Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin+ Clopidogrel Following Transcatheter Aortic Valve Implantation) randomiz.
        JACC Cardiovasc Interv. 2017; 10: 1357-1365
        • Dangas G.D.
        • Tijssen J.G.P.
        • Wöhrle J.
        • Søndergaard L.
        • Gilard M.
        • Möllmann H.
        • et al.
        A controlled trial of rivaroxaban after transcatheter aortic-valve replacement.
        N Engl J Med. 2020; 382: 120-129
        • Collet J.P.
        • Van Belle E.
        • Thiele H.
        • Portal J.J.
        • Vicaut E.
        • Montalescot G.
        • et al.
        Anti-thrombotic strategy to lower all cardiovascular and neurologic ischemic and hemorrhagic events after TransAortic Valve Implantation for Aortic Stenosis: a randomized, open-label, phase 3 trial [Conference presentation].
        American College of Cardiology Virtual Annual Scientific Session (ACC 2021). 2021; (In preparation)
        • Van Mieghem N.M.
        • Unverdorben M.
        • Hengstenberg C.
        • Möllmann M.
        • Mehran R.
        • López-Otero D.
        • et al.
        Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR.
        N Engl J Med. 2021; 385: 2150-2160
      6. Pharmaceutical Benefits Scheme. Australian statistics on medicines 2015. 2016. https://www.pbs.gov.au/statistics/asm/2015/australian-statistics-on-medicines-2015.pdf. [accessed 30.6.21].